相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy
Xu Lei et al.
CANCER LETTERS (2020)
Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy
Xiaopin Duan et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2019)
Transforming Growth Factor-β Signaling in Immunity and Cancer
Eduard Batlle et al.
IMMUNITY (2019)
Cancer nanomedicine for combination cancer immunotherapy
Jutaek Nam et al.
NATURE REVIEWS MATERIALS (2019)
FRET as a biomolecular research tool-understanding its potential while avoiding pitfalls
W. Russ Algar et al.
NATURE METHODS (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Delivery technologies for cancer immunotherapy
Rachel S. Riley et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Size-adjustable micelles co-loaded with a chemotherapeutic agent and an autophagy inhibitor for enhancing cancer treatment via increased tumor retention
Jingdong Rao et al.
ACTA BIOMATERIALIA (2019)
Cytokines in Cancer Immunotherapy
Thomas A. Waldmann
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2018)
Enhanced Tumor Retention Effect by Click Chemistry for Improved Cancer Immunochemotherapy
Ling Mei et al.
ACS APPLIED MATERIALS & INTERFACES (2018)
Nanoplatform Assembled from a CD44-Targeted Prodrug and Smart Liposomes for Dual Targeting of Tumor Microenvironment and Cancer Cells
Yaqi Lv et al.
ACS NANO (2018)
Effective treatment of the primary tumor and lymph node metastasis by polymeric micelles with variable particle sizes
Ling Mei et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models
Folashade Otegbeye et al.
PLOS ONE (2018)
Controllable Aggregation-Induced Exocytosis Inhibition (CAIEI) of Plasmonic Nanoparticles in Cancer Cells Regulated by MicroRNA
Ruo-Can Qian et al.
MOLECULAR PHARMACEUTICS (2018)
Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells
Nayoung Kim et al.
FRONTIERS IN IMMUNOLOGY (2018)
Tumor-Acidity-Cleavable Maleic Acid Amide (TACMAA): A Powerful Tool for Designing Smart Nanoparticles To Overcome Delivery Barriers in Cancer Nanomedicine
Jin-Zhi Du et al.
ACCOUNTS OF CHEMICAL RESEARCH (2018)
TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells
Hung C. Tran et al.
CLINICAL CANCER RESEARCH (2017)
Smad3 promotes cancer progression by inhibiting E4BP4-mediated NK cell development
Patrick Ming-Kuen Tang et al.
NATURE COMMUNICATIONS (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
Ligand-Mediated and Enzyme-Directed Precise Targeting and Retention for the Enhanced Treatment of Glioblastoma
Shaobo Ruan et al.
ACS APPLIED MATERIALS & INTERFACES (2017)
Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization
Qihang Sun et al.
ADVANCED MATERIALS (2017)
Immunogenic cell death in cancer and infectious disease
Lorenzo Galluzzi et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Increased Gold Nanoparticle Retention in Brain Tumors by in Situ Enzyme-Induced Aggregation
Shaobo Ruan et al.
ACS NANO (2016)
Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach
Yao Lu et al.
CANCER LETTERS (2016)
Chemotherapy and immunotherapy: mapping the road ahead
Alistair M. Cook et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy
Yongju He et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Targeting natural killer cells in cancer immunotherapy
Camille Guillerey et al.
NATURE IMMUNOLOGY (2016)
The Role of Micelle Size in Tumor Accumulation, Penetration, and Treatment
Jinqiang Wang et al.
ACS NANO (2015)
Combined cellular immunotherapy and chemotherapy improves clinical outcome in patients with gastric carcinoma
Jiuwei Cui et al.
CYTOTHERAPY (2015)
Poly (γ-glutamic acid) based combination of water-insoluble paclitaxel and TLR7 agonist for chemo-immunotherapy
Anushree Seth et al.
BIOMATERIALS (2014)
Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches
Qiong Wu et al.
CANCER LETTERS (2014)
Enhanced Retention and Cellular Uptake of Nanoparticles in Tumors by Controlling Their Aggregation Behavior
Xiangsheng Liu et al.
ACS NANO (2013)
Mechanisms of Drug Resistance in Cancer Chemotherapy: Coordinated Role and Regulation of Efflux Transporters and Metabolizing Enzymes
Ramya Krishna Vadlapatla et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Physicochemical Characteristics of Nanoparticles Affect Circulation, Biodistribution, Cellular Internalization, and Trafficking
Xiaopin Duan et al.
SMALL (2013)
Bioorthogonal Copper-Free Click Chemistry In Vivo for Tumor-Targeted Delivery of Nanoparticles
Heebeom Koo et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Strain-Promoted Catalyst-Free Click Chemistry for Rapid Construction of 64Cu-Labeled PET Imaging Probes
Kai Chen et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Pegylated Phosphotidylethanolamine Inhibiting P-Glycoprotein Expression and Enhancing Retention of Doxorubicin in MCF7/ADR Cells
Jing Wang et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
H. Cabral et al.
NATURE NANOTECHNOLOGY (2011)
Improving Drug Potency and Efficacy by Nanocarrier-Mediated Subcellular Targeting
Mami Murakami et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Development of PLGA Nanoparticles Simultaneously Loaded with Vincristine and Verapamil for Treatment of Hepatocellular Carcinoma
Xiang Rong Song et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
Rapid Cu-Free Click Chemistry with Readily Synthesized Biarylazacyclooctynones
John C. Jewett et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2010)
ABC transporters in cancer: more than just drug efflux pumps
Jamie I. Fletcher et al.
NATURE REVIEWS CANCER (2010)
TGF-β utilizes SMAD3 to inhibit CD16-mediated IFN-γ production and antibody-dependent cellular cytotoxicity in human NK cells
Rossana Trotta et al.
JOURNAL OF IMMUNOLOGY (2008)
Seven challenges for nanomedicine
Wendy R. Sanhai et al.
NATURE NANOTECHNOLOGY (2008)
Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new Polymer-Lipid Hybrid Nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer
Ho Lun Wong et al.
JOURNAL OF CONTROLLED RELEASE (2006)
Multifunctional nanocarriers
Vladimir P. Torchilin
ADVANCED DRUG DELIVERY REVIEWS (2006)
TGF-β and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells
Guenter Eisele et al.
BRAIN (2006)
Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion
YT Bryceson et al.
BLOOD (2006)
Cutting edge:: NKG2D is a costimulatory receptor for human naive CD8+ T cells
K Maasho et al.
JOURNAL OF IMMUNOLOGY (2005)
Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor
ES Lee et al.
JOURNAL OF CONTROLLED RELEASE (2005)
Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors
P André et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Drug delivery systems: Entering the mainstream
TM Allen et al.
SCIENCE (2004)
Elevated TGF-β1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients
JC Lee et al.
JOURNAL OF IMMUNOLOGY (2004)
RNA interference targeting transforming growth factor-β enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo
MA Friese et al.
CANCER RESEARCH (2004)
Transforming growth factor β1 inhibits expression of NKp30 and NKG2D receptors:: Consequences for the NK-mediated killing of dendritic cells
R Castriconi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity
A Diefenbach et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
FRET imaging
EA Jares-Erijman et al.
NATURE BIOTECHNOLOGY (2003)
分享论文
